Related Experiment Video
Updated: Jul 19, 2025
Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
Potential anti-obesity/inflammatory flavonoid-derived biomolecules against Obesity to prevent WAT differentiation by
Jowaher S Alanazi1, Aziz Unnisa2, Muteb S Alanazi3
1Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, KSA. jawaher.a@gmail.com.
Abstract:
A concoction of unhealthy eating, inactivity, and the adverse effects of specific drugs brings on obesity. The primary cause of Obesity is the storage of too much energy and triglycerides in adipocytes, particularly white adipose tissue (WAT). In addition to modifying one's lifestyle, anti-obesity medicines are increasingly used as adjuvant therapy. Flavonoids are the major class of compounds having significant biological impacts and health-improving properties. To find novel flavonoid compounds that fight obesity using computational drug design techniques. This work targets 1DI protein to predict new flavonoid compounds that fight obesity. The study uses computational approaches to anticipate potential anti-obesity/inflammatory flavonoid compounds against obesity to prevent WAT differentiation by targeting ID-1, a DNA-binding protein inhibitor. Our study led to the identification of the protein target inhibitor lead CID: 5280443, which was found to be a potent inhibitor of the receptor. According to the findings of this study, this bio-active molecule may be used as a lead for the development of drugs that preferentially fight obesity without interfering with the functions of the human proteasome. The scientific community will benefit from these discoveries, which could aid in the creation of new medications that treat obesity more successfully.
Insights
Computational drug design identified a novel flavonoid compound (CID: 5280443) that may combat obesity by inhibiting white adipose tissue differentiation. This discovery offers a promising lead for developing new anti-obesity drugs targeting the ID-1 protein.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Biology
Background:
- Obesity stems from energy imbalance, excessive triglyceride storage in white adipose tissue (WAT), and lifestyle factors.
- Anti-obesity medications are increasingly used alongside lifestyle changes.
- Flavonoids are a class of compounds known for significant biological and health-promoting effects.
Purpose of the Study:
- To identify novel flavonoid compounds with anti-obesity potential using computational drug design.
- To target the ID-1 protein, a DNA-binding protein inhibitor, to prevent WAT differentiation.
Main Methods:
- Utilized computational approaches to screen for potential anti-obesity and anti-inflammatory flavonoid compounds.
- Focused on targeting the ID-1 protein as a mechanism to inhibit WAT differentiation.
Main Results:
- Identified a specific protein target inhibitor lead, CID: 5280443.
- CID: 5280443 demonstrated potent inhibitory activity against the target receptor.
- The identified molecule shows potential for developing obesity-fighting drugs without affecting proteasome function.
Conclusions:
- The identified flavonoid compound (CID: 5280443) is a promising lead for novel anti-obesity drug development.
- This discovery could lead to more effective obesity treatments by targeting WAT differentiation via ID-1 inhibition.
- The findings benefit the scientific community by providing a potential new therapeutic strategy for obesity.
